In vitro, and in vivo, evaluation of dihydropyrimidinone C-5 amides as potent and selective α(1A) receptor antagonists for the treatment of benign prostatic hyperplasia

Journal of Medicinal Chemistry

Volumn 43, Issue 14, 2000, Pages 2703-2718

  Barrow, James C ^a   Nantermet, Philippe G ^a   Selnick, Harold G ^a   Glass, Kristen L ^a   Rittle, Kenneth E ^a   Gilbert, Kevin F ^a   Steele, Thomas G ^a   Homnick, Carl F ^a   Freidinger, Roger M ^a   Ransom, Rick W ^a   Kling, Paul ^a   Reiss, Duane ^a   Broten, Theodore P ^a   Schorn, Terry W ^a   Chang, Raymond S L ^a   O'Malley, Stacey S ^a   Olah, Timothy V ^a   Ellis, Joan D ^a   Barrish, Andrea ^a   Kassahun, Kelem ^a   Leppert, Paula ^a   Nagarathnam, Dhanapalan ^b   Forray, Carlos ^b   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3,4 DIFLUOROPHENYL) 6 METHOXYMETHYL 2 OXO 1,2,3,4 TETRAHYDROPYRIMIDINE 5 CARBOXYLIC ACID [3 [4 (4 FLUOROPHENYL)PIPERIDIN 1 YL]PROPYL]AMIDE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE; N [5 (4,5 DIHYDRO 1H IMIDAZOL 2 YL) 5,6,7,8 TETRAHYDRO 2 HYDROXY 1 NAPHTHYL]METHANESULFONAMIDE; PHENYLEPHRINE; PYRIMIDINONE DERIVATIVE; RECEPTOR SUBTYPE; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PROSTATE HYPERTROPHY; RAT; STRUCTURE ACTIVITY RELATION;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CRYSTALLOGRAPHY, X-RAY; DOGS; HUMANS; MALE; PROSTATIC HYPERPLASIA; PYRIMIDINONES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 18544397955     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990612y     Document Type: Article

References (30)

1. Berry, S. J.; Coffey, D. S.; Walsh, P. C.; Ewing, L. L. The Development of Human Benign Prostatic Hyperplasia with age. J. Urol. 1984, 132, 474-479.
2. Steers, W. D.; Zorn, B. Benign Prostatic Hyperplasia. In Disease-a-Month; Bone, R. C., Ed.; Mosby-Year Book, Inc.: St. Louis, 1995.
3. McConnell, J. D.; Bruskewitz, R.; Walsh, P.; Andriole, G.; Lieber, M.; Holtgrewe, H. L.; Albertsen, P.; Roehrborn, C. G.; Nickel, J. C.; Wang, D. Z.; Taylor, A. M.; Waldstreicher, J. The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia. N. Engl. J. Med. 1998, 338, 557-563.
4. Roehrborn, C. G.; Oesterling, J. E.; Auerbach, S.; Kaplan, S. A.; Lloyd, L. K.; Milam, D. F.; Padley, R. J. The Hytrin Community Assessment Trial Study: A One-Year Study of Terazosin Versus Placebo in the Treatment of Men with Symptomatic Benign Prostatic Hyperplasia. Urology 1996, 47, 159-168.
5. Heible, J. P.; Bylund, D. B.; Clarke, D. E.; Eikenburg, D. C.; Langer, S. Z.; Lefkowitz, R. J.; Minneman, K. P.; Ruffolo, R. R. International Union of Pharmacology X. Recommendation for Nomenclature of a1-Adrenoceptors: Consensus Update. Pharmacol. Rev. 1995, 47, 267-270.
6. 1c Subtype. Mol. Pharmacol. 1994, 45, 703-708.
7. Kawabe, K.; Ueno, A.; Takimoto, Y.; Aso, Y.; Kato, H. YM617 Clinical Study Group. Use of an Alpha-1 Blocker, YM617, in the Treatment of Benign Prostatic Hypertrophy. J. Urol. 1990, 144, 908-912.
8. Wetzel, J. M.; Miao, S. W.; Forray, C.; Borden, L. A.; Branchek, T. A.; Gluchowski, C. Discovery of alpha 1 a-adrenergic receptor Antagonists Based on the L-Type Ca2+ Channel Antagonist Niguldipine. J. Med. Chem. 1995, 38, 1579-1581.
9. Atwal, K. S.; Rovnyak, G. C.; Schwartz, J.; Moreland, S.; Hedberg, A.; Gougoutas, J. Z.; Malley, M. F.; Floyd, D. M. J. Med. Chem. 1990, 33, 1510.
10. Nagarathnam, D.; Miao, S. W.; Chiu, G.; Fang, J.; Gluchowski, C.; Forray, C. Design, Synthesis and Evaluation of Dihydropyrimidinones as alpha 1A selective Antagonists: 1. Identification of SNAP 5582 as a Novel Lead. Presented at the 214th National Meeting of the American Chemical Society, Las Vegas, NV, September 1997; MEDI 82.
11. Nagarathnam, D.; Miao, S. W.; Lagu, B.; Chiu, G.; Fang, J.; Murali Dhar, T. G.; Zhang, J.; Tyagarajan, S.; Marzabadi, M. R.; Zhang, F.; Wong, W. C.; Sun, W.; Tian, D.; Wetzel, J. M.; Forray, C.; Chang, R. S. L.; Broten, T. P.; Ransom, R. W.; Schorn, T. W.; Chen, T. B.; O'Malley, S.; Kling, P.; Schneck, K.; Bendesky, R.; Harrell, C. M.; Vyas, K. P.; Gluchowski, C. Design and Synthesis of Novel alpha 1A Adrenoceptor-Selective Antagonists. 1. Structure-Activity Relationship in Dihydropyrimidinones. J. Med. Chem. 1999, 42, 4764-4777.
12. Murali Dhar, T. G.; Nagarathnam, D.; Marzabadi, M. R.; Lagu, B.; Wong, W. C.; Chiu, G.; Tyagarajan, S.; Miao, S. W.; Zhang, F.; Sun, W.; Tian, D.; Shen, Q.; Zhang, J.; Wetzel, J. M.; Forray, C.; Chang, R. S. L.; Broten, T. P.; Schorn, T. W.; Chen, T. B.; O'Malley, S.; Ransom, R. W.; Schneck, K.; Bendesky, R.; Harrell, C. M.; Vyas, K. P.; Zhang, K.; Gilbert, J.; Pettibone, D. J.; Patane, M. A.; Bock, M. G., Freidinger, R. M.; Gluchowski, C. Design, and Synthesis of Novel alpha 1A Adrenoceptor-Selective Antagonists. 2. Approaches to Eliminate Opioid Agonist Metabolites via Modification of Linker and 4-Methoxycarbonyl-4-phenylpiperidine Moiety. J. Med. Chem. 1999, 42, 4778-4793.
13. Wong, W. C.; Sun, C.; Lagu, B.; Tian, D.; Marzabadi, M. R.; Zhang, F.; Nagarathnam, D.; Miao, S. W.; Wetzel, J. M.; Peng, J.; Forray, C.; Chang, R. S. L.; Chen, T. B.; Ransom, R. W.; O'Malley, Broten, T. P.; Kling, P.; Vyas, K. P.; Zhang, K.; Gluchowski, C. Design, and Synthesis of Novel alpha 1A Adrenoceptor-Selective Antagonists. 4. Structure-Activity Relationship in the Dihydropyrimidine Series. J. Med. Chem. 1999, 42, 4804-4813.
14. Lagu, B.; Tian, D.; Nagarathnam, D.; Marzabadi, M. R.; Wong, W. C.; Miao, S. W.; Zhang, F.; Sun, C.; Chiu, G.; Fang, J.; Forray, C.; Chang, R. S. L.; Ransom, R. W.; Chen, T. B.; O'Malley, Zhang, K.; Vyas, K. P.; Gluchowski, C. Design, and Synthesis of Novel alpha 1A Adrenoceptor-Selective Antagonists. 3. Approaches to Eliminate Opioid Agonist Metabolites by Using Substituted Phenylpiperazine Side Chains. J. Med. Chem. 1999, 42, 4794-4803.
15. Nagarathnam, D.; Wong, W. C.; Lagu, B.; Miao, S. W.; Tyagarajan, S.; Sun, W.; Shen, D.; Tian, D.; Tang, C.; MuraliDhar, T. G.; Marzabadi, M. R.; Forray, C.; Gluchowski, C.; Chang, R.; Broten, T.; Schorn, T. W.; Chen, T. B.; O'Malley, S. O.; Ransom, R.; Schneck, K.; Bendesky, R.; Harrell, C. M.; Vyas, K.; Zhang, J.; Gilbert, J.; Pettibone, D. J.; Freidinger, R. M. Design, Synthesis and Evaluation of Dihydropyrimidinones and Dihydropyrimidines as Alpha 1A Selective Antagonists. Modification of the Diaryl Piperidine Moiety. Presented at the 215th National Meeting of the American Chemical Society, Dallas, TX, March 1998; MEDI 67.
16. Hu, E. H.; Sidler, D. R.; Dolling, U.-H. Unprecedented Catalytic Three Component One-Pot Condensation Reaction: An efficient Synthesis of 5-Alkoxycarbonyl-4-aryl-3,4-dihydropyrimidin-2(1H)-ones. J. Org. Chem. 1998, 63, 3454-3457.
17. (a) Ikemoto, N. Manuscript in preparation.
18. (b) Roberge, C. M.; Li, W.; Bills, G. F.; Larsen, R. D.; Sidler, D. R.; Chartrain, M.; Ikemoto, N.; Taylor, C. S. PCT Int. Appl. WO9907695, 1999; Chem. Abstr. 1999, 130, 182478.
19. Steele, T. G.; Coburn, C. A.; Patane, M. A.; Bock, M. G. Expedient Synthesis of 5-Unsubstituted 3,4-Dihydropyrimidin-2(1H)-ones. Tetrahedron Lett. 1998, 39, 9315-9318.
20. The stereochemistry of 9a was assigned by (1) comparison of the optical rotation with the sample obtained from the partial enzymatic hydrolysis of 7a, which is assumed to proceed in a stereoregular manner and (2) relative potency of the final compounds containing this subunit.
21. Kappe, C. O. 100 Years of the Biginelli Dihydropyrimidine Synthesis. Tetrahedron 1993, 49, 6937-6963.
22. 1D described the pharmacologically characterized receptors; see refs 5 and 6.
23. O'Malley, S. S.; Chen, T. B.; Francis, B. E.; Gibson, R. E.; Burns, H. D.; DiSalvo, J.; Bayne, M. L.; Wetzel, J. M.; Nagarathnam, D.; Marzabadi, M.; Gluchowski, C.; Chang, R. S. L. Characterization of specific binding of [125I]L-762,459, a selective α1A-adrenoceptor radioligand to rat and human tissues. Eur. J. Pharm. 1988, 348, 287-295.
24. (a) Knepper, S. M.; Buckner, S. A.; Brune, M. E.; DeBernardis, J. F.; Meyer, M. D.; Hancock, A. A. A-61603, a Potent α1-adrenergic receptor agonist, selective for the α1a receptor subtype. J. Pharmacol. Exp. Ther. 1995, 274, 97-103.
25. (b) Meyer, M. D.; Altenbach, R. J.; Hancock, A.; Buckner, S. A.; Knepper, S. M.; Kerwin, J. F. Synthesis and in Vitro Characterization of N-[5-(4,5-Dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl] methanesulfonamide and its Enantiomers: A Novel Selective α1A Receptor Agonist. J. Med. Chem. 1996, 39, 4116-4119.
26. Artursson, P. Epithelial Transport of Drugs in Cell Culture. I: A Model for Studying the Passive Diffusion of Drugs over Intestinal Absorbtive (Caco-2) Cells. J. Pharm. Sci. 1990, 79, 476-482.
27. For a similar study, see also: Tucker, J. A.; Allwine, D. A.; Grega, K. C.; Barbachyn, M. R.; Klock, J. L.; Adamski, J. L.; Brickner, S. J.; Hutchinson, D. K.; Ford, C. W.; Zurenko, G. E.; Conradi, R. A.; Burton, P. S.; Jensen, R. M. Piperazinyl Oxazolidinone Antibacterial Agents Containing a Pyridine, Diazene, or Triazine Heteroaromatic Ring. J. Med. Chem. 1998, 41, 3727-3735.
28. Brune, M. E.; Buckner, S. A.; Polakowski, J.; Kerwin, J. F., Jr.; Hancock, A. A. Pharmacological Antagonism of Alpha-adrenergic Agonist Increases in Canine Intra-Urethral Pressure in vivo. Drug Dev. Res. 1995, 34, 267-275.
29. Sheldrick, G. M. Acta Crystallogr. 1990, A46, 467-473.
30. Sheldrick, G. M. SHELXL-93. Program for the Refinement of Crystal Structures; University of Gottingen: Germany.